98%
921
2 minutes
20
Aim: To summarise key epidemiological and therapeutic research on osteoarthritis (OA) published between April 2024 and March 2025.
Methods: A narrative review was conducted using the MEDLINE database, focusing on English-language studies involving human participants published between April 1, 2024 and March 31, 2025. Eligible studies included observational longitudinal studies, systematic reviews, meta-analyses, and phase II-IV randomised controlled trials (RCTs) examining OA treatment and epidemiology. A total of 1920 studies were screened by 3 authors, resulting in 133 studies considered for potential inclusion. Ultimately, 41 studies were selected. Inclusion was based on perceived importance and relevance to identifying risk factors or advancing OA treatment.
Results: The global burden of OA continues to rise, with a notable increase in early-onset OA, driven in part by obesity and joint injuries. Epidemiologically, body composition-characterised by high fat mass and low lean mass-emerged as a critical factor influencing OA severity and physical function. Furthermore, the presence of other chronic conditions significantly impacts OA progression and outcomes, and influences management choice, increasing the risk of patients receiving low-value care. Therapeutic interventions for OA, including intra-articular injections (e.g., corticosteroids, hyaluronic acid, stem cells) and pharmacological therapies (e.g., metformin, methotrexate), continue to show limited efficacy. Semaglutide, which targets obesity, demonstrated substantial weight and pain reductions in individuals with knee OA and obesity, suggesting a potential disease-modifying effect through weight loss.
Conclusion: The past year's research highlights the complexity of OA and the limited effectiveness of current interventions. While therapies targeting obesity hold promise, further research is needed to confirm their role in disease modification. Personalised treatment approaches that integrate metabolic, biomechanical, and psychosocial factors may be crucial for advancing OA care management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.joca.2025.08.015 | DOI Listing |
Pest Manag Sci
September 2025
IRTA, Postharvest, Fruitcentre, Lleida, Spain.
Background: Almond blossom blight, caused by Monilinia spp., is a notable fungal disease associated with intensified crop management practices. In this study, we aimed to investigate the epidemiology of Monilinia spp.
View Article and Find Full Text PDFOsteoarthritis Cartilage
September 2025
Clinical Epidemiology Unit, Orthopaedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address:
Aim: To summarise key epidemiological and therapeutic research on osteoarthritis (OA) published between April 2024 and March 2025.
Methods: A narrative review was conducted using the MEDLINE database, focusing on English-language studies involving human participants published between April 1, 2024 and March 31, 2025. Eligible studies included observational longitudinal studies, systematic reviews, meta-analyses, and phase II-IV randomised controlled trials (RCTs) examining OA treatment and epidemiology.
Sleep Med Rev
August 2025
Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, Viale Del Tirreno. 341/A/B/C, Calambrone, Pisa, 56128 Italy; Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Via Savi 10, 56126, Pisa, Italy.
Melatonin is known to be effective in improving sleep in pediatric patients affected by neurological and psychiatric conditions. However, no guidelines exist advising the most effective treatment schedule. This systematic review and meta-analysis aimed to identify the dose, time of administration and treatment duration associated with the maximal treatment efficacy.
View Article and Find Full Text PDFWellcome Open Res
July 2025
Social Science, Africa Health Research Institute, Durban, KwaZulu-Natal, 4001, South Africa.
Background: Adolescents and young people (AYP) aged 10-24 years in Africa experience a high burden of mental health disorders but face significant barriers to accessing care, including a severe shortage of mental health professionals, stigma, and limited integration of mental health services into primary healthcare. Digital mental health interventions (DMHIs) offer a promising avenue to bridge these gaps by providing accessible, scalable, and potentially equitable support. However, little is known about the effectiveness, acceptability, and equity impacts of these interventions among African AYP.
View Article and Find Full Text PDFLancet Child Adolesc Health
October 2025
Uehiro Oxford Institute, University of Oxford, Oxford, UK; Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
The potential use of psychedelic-assisted therapy for adolescents with mental illness has sparked both interest and concern. Modern psychedelic research has focused on adults, and adolescents younger than 18 years are typically excluded due to ethical and legal challenges. To explore whether adolescents have been included in 21st century psychedelic research, we conducted a scoping review of the medical literature from January, 2000, to April, 2025.
View Article and Find Full Text PDF